Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

BACKGROUND: Treatment of non‐small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune‐oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cufer, Tanja, Ciuleanu, Tudor E., Berzinec, Peter, Galffy, Gabriela, Jakopovic, Marko, Jassem, Jacek, Jovanovic, Dragana, Mihaylova, Zhasmina, Ostoros, Gyula, Thallinger, Christiane, Zemanova, Milada, Zielinski, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066717/
https://www.ncbi.nlm.nih.gov/pubmed/32162818
http://dx.doi.org/10.1634/theoncologist.2019-0523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066717/
https://www.ncbi.nlm.nih.gov/pubmed/32162818
http://dx.doi.org/10.1634/theoncologist.2019-0523

Ejemplares similares